University of Central Florida   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Orlando FL United States (1963)

Organization Overview

First Clinical Trial
2001
NCT00043537
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

David Weinstein | Erica Goldstein | University of Cenral Florida | University of Central Florida

Active Ingredients

Drugs in Phase 4 Trials (3)

abobotulinumtoxinA (Dysport) (1 trial)

acetaminophen (tylenol) (1 trial)

sodium thiosulfate (1 trial)

Drugs in Phase 3 Trials (1)

fluoxetine (prozac) (1 trial)

Drugs in Phase 2 Trials (1)

nivolumab (opdivo) (1 trial)

Drugs in Other Trials (3)

bacillus coagulans (1 trial)

beta-hydroxyisovaleric acid (2 trials)

fentanyl (Innovar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Calcinosis (Phase 4)

Pain, Postoperative (Phase 4)

Phobia, Social (Phase 3)

Phobic Disorders (Phase 3)

Prostatic Diseases (Phase 2)

Prostatic Neoplasms (Phase 2)

Raynaud Disease (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 8